# Filing Detail

Form 8-K - Current report:
SEC Accession No. 0000950170-25-061441
Filing Date
2025-05-01
Accepted
2025-05-01 07:05:12
Documents
29
Period of Report
2025-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 8-K | alks-20250501.htm iXBRL | 8-K | 58535
2 | EX-99.1 | alks-ex99_1.htm | EX-99.1 | 315202
3 | EX-99.2 | alks-ex99_2.htm | EX-99.2 | 15222
4 | GRAPHIC | alks-ex99_2s1.jpg | GRAPHIC | 225856
5 | GRAPHIC | alks-ex99_2s2.jpg | GRAPHIC | 684038
6 | GRAPHIC | alks-ex99_2s3.jpg | GRAPHIC | 120366
7 | GRAPHIC | alks-ex99_2s4.jpg | GRAPHIC | 224345
8 | GRAPHIC | alks-ex99_2s5.jpg | GRAPHIC | 261644
9 | GRAPHIC | alks-ex99_2s6.jpg | GRAPHIC | 246209
10 | GRAPHIC | alks-ex99_2s7.jpg | GRAPHIC | 356778
11 | GRAPHIC | alks-ex99_2s8.jpg | GRAPHIC | 109534
12 | GRAPHIC | alks-ex99_2s9.jpg | GRAPHIC | 275061
13 | GRAPHIC | alks-ex99_2s10.jpg | GRAPHIC | 269109
14 | GRAPHIC | alks-ex99_2s11.jpg | GRAPHIC | 260318
15 | GRAPHIC | alks-ex99_2s12.jpg | GRAPHIC | 97373
16 | GRAPHIC | alks-ex99_2s13.jpg | GRAPHIC | 206764
17 | GRAPHIC | alks-ex99_2s14.jpg | GRAPHIC | 286639
18 | GRAPHIC | alks-ex99_2s15.jpg | GRAPHIC | 237430
19 | GRAPHIC | alks-ex99_2s16.jpg | GRAPHIC | 134333
| Complete submission text file | 0000950170-25-061441.txt |  | 6033042

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
20 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | alks-20250501.xsd | EX-101.SCH | 30800
32 | EXTRACTED XBRL INSTANCE DOCUMENT | alks-20250501_htm.xml | XML | 4683

Mailing Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000
Business Address CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 L2 00000 00-353-1-772-8000
Alkermes plc. (Filer) CIK: 0001520262 (see all company filings)

EIN.: 981007018 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35299 | Film No.: 25899357
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)